In vitro manipulation of peripheral blood progenitor cell collections

Research output: Contribution to journalArticle

Abstract

Mobilized peripheral blood progenitor cells (PBPC) are increasingly used to reconstitute hematopoiesis in patients undergoing high-dose chemoradiotherapy. PBPC collections comprise a heterogeneous population containing both committed progenitors and pluripotent stem cells and can be harvested (i) in steady state, (ii) after chemotherapeutic conditioning, (iii) growth factor priming, or (iv) both. The use of PBPC has opened new therapeutic perspectives mainly related to the availability of large amounts of mobilized hematopoietic stem and progenitor cells. Extensive manipulation of the grafts, including the possibility of exploiting these cells as vehicles for gene therapy strategies, are now possible and will be reviewed.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalInternational Journal of Artificial Organs
Volume21
Issue numberSUPPL. 6
Publication statusPublished - 1998

Fingerprint

Blood Cells
Blood
Stem Cells
Hematopoietic Stem Cells
Chemoradiotherapy
Gene therapy
Pluripotent Stem Cells
Hematopoiesis
Stem cells
Grafts
Genetic Therapy
Intercellular Signaling Peptides and Proteins
Availability
Transplants
Population
In Vitro Techniques
Therapeutics

Keywords

  • Autologous stem cell transplanation
  • Minimal residual disease
  • Purging

ASJC Scopus subject areas

  • Biophysics

Cite this

In vitro manipulation of peripheral blood progenitor cell collections. / Carlo-Stella, C.

In: International Journal of Artificial Organs, Vol. 21, No. SUPPL. 6, 1998, p. 1-10.

Research output: Contribution to journalArticle

@article{5c9c46e2a5e34badb94756170117f39d,
title = "In vitro manipulation of peripheral blood progenitor cell collections",
abstract = "Mobilized peripheral blood progenitor cells (PBPC) are increasingly used to reconstitute hematopoiesis in patients undergoing high-dose chemoradiotherapy. PBPC collections comprise a heterogeneous population containing both committed progenitors and pluripotent stem cells and can be harvested (i) in steady state, (ii) after chemotherapeutic conditioning, (iii) growth factor priming, or (iv) both. The use of PBPC has opened new therapeutic perspectives mainly related to the availability of large amounts of mobilized hematopoietic stem and progenitor cells. Extensive manipulation of the grafts, including the possibility of exploiting these cells as vehicles for gene therapy strategies, are now possible and will be reviewed.",
keywords = "Autologous stem cell transplanation, Minimal residual disease, Purging",
author = "C. Carlo-Stella",
year = "1998",
language = "English",
volume = "21",
pages = "1--10",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "SUPPL. 6",

}

TY - JOUR

T1 - In vitro manipulation of peripheral blood progenitor cell collections

AU - Carlo-Stella, C.

PY - 1998

Y1 - 1998

N2 - Mobilized peripheral blood progenitor cells (PBPC) are increasingly used to reconstitute hematopoiesis in patients undergoing high-dose chemoradiotherapy. PBPC collections comprise a heterogeneous population containing both committed progenitors and pluripotent stem cells and can be harvested (i) in steady state, (ii) after chemotherapeutic conditioning, (iii) growth factor priming, or (iv) both. The use of PBPC has opened new therapeutic perspectives mainly related to the availability of large amounts of mobilized hematopoietic stem and progenitor cells. Extensive manipulation of the grafts, including the possibility of exploiting these cells as vehicles for gene therapy strategies, are now possible and will be reviewed.

AB - Mobilized peripheral blood progenitor cells (PBPC) are increasingly used to reconstitute hematopoiesis in patients undergoing high-dose chemoradiotherapy. PBPC collections comprise a heterogeneous population containing both committed progenitors and pluripotent stem cells and can be harvested (i) in steady state, (ii) after chemotherapeutic conditioning, (iii) growth factor priming, or (iv) both. The use of PBPC has opened new therapeutic perspectives mainly related to the availability of large amounts of mobilized hematopoietic stem and progenitor cells. Extensive manipulation of the grafts, including the possibility of exploiting these cells as vehicles for gene therapy strategies, are now possible and will be reviewed.

KW - Autologous stem cell transplanation

KW - Minimal residual disease

KW - Purging

UR - http://www.scopus.com/inward/record.url?scp=21544469730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21544469730&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:21544469730

VL - 21

SP - 1

EP - 10

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - SUPPL. 6

ER -